Biocomposites will launch Synicem in Nice Britain for orthopedic functions
Medical system firm Biocomposites is to launch its Synicem bone cement merchandise within the UK for orthopedic surgical procedure with quick impact.
The Synicem bone cement line has been produced by Synimed, a subsidiary of Biocomposites, for greater than 25 years.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to succeed in engaged professionals throughout 36 main media platforms.
Extra data
The corporate initiated this transfer following the earlier introduction of Synicem antibiotic-laden preformed spacers in Britain final yr.
Biocomposites deliberate to launch the Synicem bone cements later, however accelerated the method in response to present demand. The merchandise carry the Conformité européenne (CE) marking and full regulatory approval to be used in Nice Britain.
The product vary consists of each excessive and low viscosity variants, supplied with or with out the antibiotic gentamicin.
Synicem bone cements are designed for protected and steady fixation between prosthesis and bone in joint substitute surgical procedures, together with surgical procedures involving irregular surfaces.
The vary consists of gentamicin-loaded choices for revision procedures and sufferers at excessive threat of an infection attributable to gentamicin-sensitive micro organism or compromised immunity.
Michael Harris, CEO of Biocomposites, mentioned: “The NHS is at present dealing with an acute bone cement provide disaster, which might result in 1000’s of orthopedic operations, comparable to hip and knee replacements, being postponed.
“We at Biocomposites – one of many few corporations on this planet that may produce bone cement at scale – need to do the whole lot we are able to to assist in order that sufferers haven’t got to attend longer than completely needed for his or her very important surgical procedures.
“We’ve got due to this fact determined to convey ahead the launch of our Synicem bone cement merchandise within the UK with quick impact, to make them accessible as rapidly as doable. We’re additionally doubling capability at our manufacturing facility, primarily to assist meet UK demand. We’re assured that these measures will go a great distance in assembly NHS demand for bone cement and minimizing delays to operations.”
In September 2024, Biocomposites started UK distribution of its NanoBone product vary.
